IMRSQ: AI 评分 46/100 — AI 分析 (4月 2026)

IMRIS Inc. specializes in image-guided therapy solutions, offering VISIUS Surgical Theatres that integrate advanced imaging technologies directly into surgical environments. These solutions aim to enhance surgical precision and decision-making for neurosurgical, spinal, cerebrovascular, and cardiovascular procedures.

Key Facts: AI Score: 46/100 Sector: Healthcare

公司概况

概要：

IMRIS Inc. provides image-guided therapy solutions, featuring VISIUS Surgical Theatres which integrate MRI, CT, and fluoroscopy into surgical suites. Targeting neurosurgical, spinal, cerebrovascular, and cardiovascular markets, IMRIS aims to improve surgical precision and outcomes through advanced intraoperative imaging, operating with a negative profit margin.

IMRSQ是做什么的？

Founded in 2005 and based in Winnipeg, Canada, IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions. The company's core offering is the VISIUS Surgical Theatre, an advanced surgical environment that incorporates intraoperative imaging technologies such as magnetic resonance imaging (MRI), computed tomography (CT), and fluoroscopy directly into the operating room (OR). This integration allows clinicians to visualize the surgical site in real-time, enhancing precision and facilitating informed decision-making during complex procedures. IMRIS's VISIUS Surgical Theatres are designed to support a range of medical applications, primarily focusing on neurosurgical, spinal, cerebrovascular, and cardiovascular interventions. By bringing advanced imaging capabilities into the OR, IMRIS aims to improve surgical outcomes, reduce the need for repeat procedures, and enhance patient safety. The company's solutions are sold to hospitals and medical centers worldwide, providing them with the tools to deliver cutting-edge clinical services. In addition to its VISIUS Surgical Theatre, IMRIS provides ongoing service and extended maintenance contracts to ensure the continued performance and reliability of its systems. The company also offers a range of accessories and disposables to support the use of its imaging technologies. With a focus on innovation and clinical excellence, IMRIS seeks to advance the field of image-guided therapy and improve the lives of patients around the world.

IMRSQ的投资论点是什么？

IMRIS Inc. operates in the niche market of intraoperative imaging solutions, offering a potentially valuable technology with its VISIUS Surgical Theatre. The company's ability to integrate MRI, CT, and fluoroscopy into surgical suites provides a unique selling proposition. However, the company's negative profit margin of -105.2% raises concerns about its financial sustainability. Growth catalysts include potential expansion into new therapeutic areas and geographic markets. The company's high beta of 7.79 indicates significant volatility, reflecting the speculative nature of the stock. Investors should carefully consider the risks associated with the company's financial performance and market position.

IMRSQ在哪个行业运营？

IMRIS Inc. operates within the medical specialties sector, which is characterized by technological advancements and increasing demand for minimally invasive surgical procedures. The integration of advanced imaging technologies into surgical environments is a growing trend, driven by the need for greater precision and improved patient outcomes. The competitive landscape includes companies like AMPE, BLMS, BTTX, CENBF, and DMSI, which offer various medical imaging and surgical solutions. The market for image-guided therapy is expected to grow, driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in imaging technologies.

Medical - Specialties

Healthcare

IMRSQ有哪些增长机遇？

Expansion into Emerging Markets: IMRIS Inc. has the opportunity to expand its presence in emerging markets, where there is a growing demand for advanced medical technologies. These markets often have less established healthcare infrastructure, presenting an opportunity for IMRIS to introduce its VISIUS Surgical Theatre and establish a strong foothold. The timeline for this expansion would involve market research, regulatory approvals, and strategic partnerships with local hospitals and medical centers. This could significantly increase the company's revenue and market share.
Development of New Applications: IMRIS Inc. can explore new applications for its VISIUS Surgical Theatre beyond its current focus on neurosurgical, spinal, cerebrovascular, and cardiovascular markets. This could involve adapting the technology for use in other surgical specialties, such as orthopedic surgery, oncology, or robotic surgery. By expanding its applications, IMRIS can broaden its customer base and increase the demand for its products. The timeline for developing new applications would involve research and development, clinical trials, and regulatory approvals.
Strategic Partnerships and Collaborations: IMRIS Inc. can pursue strategic partnerships and collaborations with other companies in the medical technology industry. This could involve partnering with companies that specialize in surgical robotics, medical imaging, or healthcare IT solutions. By collaborating with other companies, IMRIS can leverage their expertise and resources to enhance its product offerings and expand its market reach. The timeline for establishing strategic partnerships would involve identifying potential partners, negotiating agreements, and integrating their technologies into IMRIS's solutions.
Focus on Service and Maintenance Contracts: IMRIS Inc. can focus on growing its service and maintenance contract business. These contracts provide a recurring revenue stream and help to build long-term relationships with customers. By offering comprehensive service and maintenance packages, IMRIS can ensure the continued performance and reliability of its VISIUS Surgical Theatres, while also generating a steady stream of revenue. The timeline for growing the service and maintenance business would involve developing attractive service packages, training service technicians, and marketing the benefits of these contracts to customers.
Technological Advancements and Innovation: IMRIS Inc. can invest in research and development to further advance its imaging technologies and develop new features for its VISIUS Surgical Theatre. This could involve incorporating artificial intelligence (AI) and machine learning (ML) algorithms to enhance image quality, automate surgical workflows, and provide real-time decision support to surgeons. By staying at the forefront of technological innovation, IMRIS can maintain its competitive advantage and attract new customers. The timeline for technological advancements would involve ongoing research and development efforts, clinical trials, and regulatory approvals.

IMRIS Inc. operates with a market capitalization of $0.00B, indicating its small size and potential volatility.
The company's Price-to-Earnings (P/E) ratio is -0.00, reflecting its lack of profitability.
IMRIS Inc. has a negative profit margin of -105.2%, indicating significant operational challenges.
The company's gross margin stands at 34.4%, suggesting some ability to generate revenue from its products and services.
IMRIS Inc. exhibits a high beta of 7.79, indicating substantial volatility relative to the market.

IMRSQ提供哪些产品和服务？

Designs and manufactures image-guided therapy solutions.
Offers VISIUS Surgical Theatres, integrating MRI, CT, and fluoroscopy into surgical suites.
Provides intraoperative vision to clinicians for enhanced surgical precision.
Sells VISIUS Surgical Theatres to hospitals for neurosurgical, spinal, cerebrovascular, and cardiovascular markets.
Offers service and extended maintenance contracts.
Provides accessories and disposables for its imaging systems.

IMRSQ如何赚钱？

Sells VISIUS Surgical Theatres to hospitals and medical centers.
Generates revenue through service and extended maintenance contracts.
Sells accessories and disposables related to its imaging systems.

Hospitals that deliver clinical services to patients.
Medical centers specializing in neurosurgery, spinal surgery, cerebrovascular surgery, and cardiovascular surgery.
Healthcare providers seeking advanced intraoperative imaging solutions.

Proprietary VISIUS Surgical Theatre technology integrating multiple imaging modalities.
Specialized expertise in intraoperative imaging and image-guided therapy.
Established relationships with hospitals and medical centers in key markets.
Service and maintenance contracts providing recurring revenue.

什么因素可能推动IMRSQ股价上涨？

Ongoing: Potential expansion into new therapeutic areas, such as orthopedic surgery or oncology.
Ongoing: Development of new applications for the VISIUS Surgical Theatre.
Upcoming: Strategic partnerships with companies in related medical technology fields.
Ongoing: Technological advancements in AI and machine learning to enhance imaging capabilities.
Ongoing: Growth in service and maintenance contract revenue.

IMRSQ的主要风险是什么？

Ongoing: Negative profit margin raises concerns about financial sustainability.
Potential: High beta indicates significant stock volatility.
Potential: Competition from established medical imaging and surgical equipment companies.
Potential: Regulatory hurdles and lengthy approval processes for new medical devices.
Potential: Economic downturns affecting hospital capital expenditure budgets.

IMRSQ的核心优势是什么？

Innovative VISIUS Surgical Theatre technology.
Integration of multiple imaging modalities in a single surgical suite.
Potential to improve surgical precision and patient outcomes.
Service and maintenance contracts provide recurring revenue.

IMRSQ的劣势是什么？

Negative profit margin indicates financial instability.
High beta suggests significant stock volatility.
Limited market capitalization restricts growth potential.
Dependence on capital equipment sales can lead to revenue fluctuations.

IMRSQ有哪些机遇？

Expansion into emerging markets with growing healthcare demand.
Development of new applications for VISIUS Surgical Theatre in other surgical specialties.
Strategic partnerships with companies in related medical technology fields.
Technological advancements in AI and machine learning to enhance imaging capabilities.

IMRSQ面临哪些威胁？

Competition from established medical imaging and surgical equipment companies.
Regulatory hurdles and lengthy approval processes for new medical devices.
Economic downturns affecting hospital capital expenditure budgets.
Technological obsolescence if competitors develop superior imaging solutions.

IMRSQ的竞争对手是谁？

Ampio Pharmaceuticals, Inc. — Focuses on developing therapies for inflammatory conditions. — (AMPE)
BioLife Solutions, Inc. — Provides biopreservation tools and services for cell and gene therapies. — (BLMS)
Better Therapeutics, Inc. — Develops prescription digital therapeutics for cardiometabolic diseases. — (BTTX)
Cen Biotech, Inc. — Focuses on pharmaceutical products. — (CENBF)
DecisionPoint Systems, Inc. — Provides mobility-first enterprise solutions and services. — (DMSI)

Key Metrics

MoonshotScore: 46/100

Company Profile

CEO: Shalabh Chandra
Employees: 121
Founded: 2023

AI Insight

AI analysis pending for IMRSQ

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does IMRIS Inc. do?

IMRIS Inc. specializes in the design, manufacture, and sale of image-guided therapy solutions. Its primary product, the VISIUS Surgical Theatre, integrates advanced imaging technologies like MRI, CT, and fluoroscopy directly into surgical environments. This allows clinicians to visualize the surgical site in real-time, enhancing precision and facilitating informed decision-making during complex procedures. IMRIS targets hospitals and medical centers, particularly those specializing in neurosurgery, spinal surgery, cerebrovascular surgery, and cardiovascular surgery, offering them advanced tools to improve surgical outcomes.

What do analysts say about IMRSQ stock?

AI analysis is currently pending for IMRSQ stock. However, based on available financial data, IMRIS Inc. operates with a negative profit margin and a high beta, indicating significant financial challenges and stock volatility. The company's small market capitalization also suggests limited growth potential. Investors should carefully consider these factors and conduct thorough due diligence before investing in IMRSQ stock. Awaiting the AI analysis will provide further insights into the stock's potential and risks.

What are the main risks for IMRSQ?

IMRIS Inc. faces several key risks, including its negative profit margin, which raises concerns about its long-term financial viability. The company's high beta indicates significant stock volatility, making it a potentially risky investment. Competition from larger, more established medical imaging and surgical equipment companies poses a threat to IMRIS's market share. Additionally, regulatory hurdles and lengthy approval processes for new medical devices could delay the introduction of new products and limit the company's growth potential. Economic downturns affecting hospital capital expenditure budgets could also negatively impact IMRIS's sales.